Anupam Rasayan India Ltd (ANURAS) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Anupam Rasayan India Ltd on NSE and BSE, with an AI summary of each filing.
Intimation of Earnings Call on the Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2026.
Intimation · 06 Nov 2026, 5:00 pm
Anupam Rasayan Schedules Q2 & H1FY27 Earnings Conference Call Anupam Rasayan India Ltd. will host its earnings conference call on Friday, 6th Nov'26, at 05:00 PM IST to discuss its unaudited standalone and consolidated financial and operational performance for Q2 and H1FY27 ended 30th Sep'26. Senior management, including Managing Director Anand Desai, CEO Gopal Agrawal, CFO Amit Khurana, Deputy CFO Hetvi Vyas, and Advisor Vishal Thakkar, will represent the company. Dial-in access is available via primary Indian numbers (+91 22 6280 1488 / +91 22 7115 8869) alongside international toll-free lines.
ANUPAM RASAYAN INDIA LIMITED has informed the Exchange about Board Meeting to be held on 06-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 06 Nov 2026, 5:30 am
To consider and approve the Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026
Intimation · 06 Nov 2026, 5:30 am
Anupam Rasayan India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2026 ,inter alia, to consider and approve the Unaudited Financial ....
Intimation · 06 Nov 2026, 5:30 am
Anupam Rasayan Schedules Board Meeting to Approve Q2 Results Anupam Rasayan India Ltd has scheduled its Board of Directors meeting for 6th Nov'26 to consider and approve the standalone and consolidated unaudited financial results for the quarter and half-year ended 30th Sep'26. Additionally, the trading window for dealing in company securities, which closed on 1st Oct'26, will reopen on 8th Nov'26, 48 hours following the earnings declaration.
Anupam Rasayan India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2026 ,inter alia, to consider and approve the Unaudited Financial ....
Intimation · 06 Nov 2026, 5:30 am
Anupam Rasayan Schedules Board Meeting to Approve Q2 Results Anupam Rasayan India Ltd has informed exchanges that its Board of Directors is scheduled to meet on 6th Nov'26 to consider and approve the standalone and consolidated unaudited financial results for the quarter and half-year ended 30th Sep'26. Additionally, the trading window for dealing in company securities, which closed on 1st Oct'26, will reopen on 8th Nov'26, 48 hours post the declaration of the financial results.
Submission of minutes of the 23rd Annual General Meeting of members of the Company held on Wednesday, September 30, 2026.
Annual General Meeting · 28 Oct 2026, 10:57 pm
The Company has informed the Exchange about intimation of ESG Rating.
Others (Uncategorized) · 14 Oct 2026, 6:14 pm
Crisil Assigns Strong Core ESG Rating to Anupam Rasayan Crisil ESG Ratings & Analytics has reviewed Anupam Rasayan India Ltd. and assigned it an ESG rating of 'Crisil ESG 62' alongside a Core ESG rating of 'Crisil Core ESG 63' (Strong) as of 14th Oct'26. The evaluation was prepared independently based on publicly available data, without direct engagement from the company.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd
Acquisition/ Disposal of Shares · 08 Oct 2026, 2:44 pm
Catalyst Trusteeship Discloses Additional Share Pledge in Anupam Rasayan India Catalyst Trusteeship Limited, acting as Debenture Trustee for debenture holders, acquired an encumbrance/pledge of 24,62,215 equity shares (2.16% stake) of Anupam Rasayan India Limited on 5th Oct'26. Following this transaction, total encumbered holdings increased from 1,69,66,785 shares (14.90%) to 1,94,29,000 shares, representing 17.07% of the company's total voting capital of 11,38,49,841 shares (INR 1.14B paid-up equity).
The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on October ....
Encumbered Shares - Invocation / Release · 06 Oct 2026, 4:09 pm
Anupam Rasayan Promoter Pledges Shares for Subsidiary NCD Issuance and Acquisition Financing Anupam Rasayan India promoter Mona Anandbhai Desai reported share encumbrance updates under SEBI SAST regulations. Between 23rd Sep'26 and 30th Sep'26, Desai created pledges on 40,40,625 shares (3.55% of total share capital, representing 97.58% of her 3.64% holding) in favor of Catalyst Trusteeship, after releasing 26,80,000 previously encumbered shares on 29th Sep'26. The pledge secures INR 578 crore unrated, unlisted NCDs across Mates Visa Consultancy (INR 300 crore to consummate Bliss GVS Pharma's acquisition) and Rehash Industrial and Resins Chemicals (INR 278 crore for promoter debt refinancing).
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 06, 2026 for Mona Anandbhai Desai
Encumbered Shares - Invocation / Release · 06 Oct 2026, 4:00 pm
Anupam Rasayan Promoter Pledges Shares for Subsidiary NCD Borrowings Anupam Rasayan India disclosed encumbrance activities by promoter Mona Anandbhai Desai, who holds a 3.64% stake (41,40,625 shares). On 29th Sep'26, pledges on 26,80,000 shares (2.38%) were released following debt repayments to STCI Finance and Aditya Birla Capital. Subsequently, on 23rd Sep'26 and 30th Sep'26, pledges were created on 14,60,625 shares (1.28%) and 25,80,000 shares (2.27%) in favor of Catalyst Trusteeship. Consequently, total encumbered promoter holding stands at 97.58% (3.55% of total capital), securing ₹578 crore unrated NCDs to fund Bliss GVS Pharma acquisition and retire debt.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd
Acquisition/ Disposal of Shares · 06 Oct 2026, 3:57 pm
Catalyst Trusteeship Increases Pledged Stake in Anupam Rasayan to 14.90% Catalyst Trusteeship Ltd, acting as Debenture Trustee, created an additional encumbrance on 66,05,000 equity shares (5.80% of total voting capital) of Anupam Rasayan India Ltd on 30th Sep'26. Following this transaction, total encumbered shares held by the trustee increased from 1,03,61,785 shares (9.10%) to 1,69,66,785 shares, representing 14.90% of the company's total and diluted equity share capital of 11,38,49,841 shares (face value Rs. 10 each).
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 03, 2026 for Rehash Industrial ....
Encumbered Shares - Invocation / Release · 05 Oct 2026, 5:01 pm
Promoter Rehash Industrial Releases Entire Pledged Stake in Anupam Rasayan Promoter Rehash Industrial and Resins Chemicals Private Limited released a pledge on 50,00,000 equity shares (4.39% of total share capital) of Anupam Rasayan India Limited on 24th Sep'26, following the complete repayment of a loan from Tata Capital Limited. Prior to this release, the entity held 72,17,040 shares (6.34% stake) with 50,00,000 encumbered shares. Post-transaction, its encumbered holding stands reduced to nil (0.00%), fully unencumbering its entire equity stake in the company.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 03, 2026 for Mona Anandbhai Desai
Encumbered Shares - Invocation / Release · 05 Oct 2026, 5:00 pm
Anupam Rasayan Promoter Pledges Additional 1.28% Stake for Subsidiary NCDs Mona Anandbhai Desai, promoter of Anupam Rasayan India Limited, created a pledge on 14,60,625 equity shares (1.28% of total share capital) on 23rd Sep'26. The pledge was executed in favor of Catalyst Trusteeship Limited as security against non-convertible debentures issued by wholly owned subsidiary Mates Visa Consultancy Private Limited and Rehash Industrial and Resins Chemicals Private Limited. Following this transaction, Desai’s total encumbered holding increased from 26,80,000 shares (2.35%) to 41,40,625 shares (3.64%), representing 100% of her personal shareholding in the company.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 01, 2026 for Anand Sureshbhai ....
Encumbered Shares - Invocation / Release · 05 Oct 2026, 4:51 pm
Anupam Rasayan Promoters Disclose Additional Share Pledges Aggregating 10.58% Stake Anupam Rasayan India disclosed fresh share pledges by promoter group members. On 22nd Sep'26, promoter Anand Sureshbhai Desai pledged 31.40 lakh shares (2.76%) to CTL Trusteeship for INR 145 crore NCDs issued by the company. On 23rd Sep'26, Desai pledged an additional 39.01 lakh shares (3.43%) to Catalyst Trusteeship for subsidiary debt, taking his total encumbered holding to 9.55%. Concurrently, promoter group member Shraddha Anand Desai pledged 50.00 lakh shares (4.39%) to Tata Capital against a loan availed by Anand Desai, raising her encumbered stake to 4.39%.
Submission of Scrutinizer''s Report along with e-voting results of 23rd Annual General Meeting held on September 30, 2026.
Annual General Meeting · 02 Oct 2026, 1:25 am
Update on disclosure dated 28 September 2026 on the intimation of acquisition of equity shares of Bliss GVS Pharma Limited.
Others (Uncategorized) · 01 Oct 2026, 12:22 am
Anupam Rasayan and PAC Consummate Bliss GVS Pharma Share Acquisition Anupam Rasayan India Ltd. and person acting in concert (PAC) Mates Visa Consultancy consummated transactions under the Share Purchase Agreement on 28th Sep'26 for acquiring equity shares of Bliss GVS Pharma Ltd. Under the deal, the PAC acquired 5,09,84,595 equity shares (47.95% stake). Clarifying prior typographical disclosures, Anupam Rasayan holds 22,51,669 shares (including 1,669 shares credited on 24th Aug'26 plus 22,50,000 shares), while the PAC holds 5,09,84,595 shares, completing the underlying acquisition structure alongside the open offer.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 30, 2026 for Anand Sureshbhai Desai
Encumbered Shares - Invocation / Release · 30 Sept 2026, 11:28 pm
Anupam Rasayan Promoter Releases Pledge on 2.93% Equity Stake Anand Sureshbhai Desai, promoter of Anupam Rasayan India Limited, announced the release of a pledge on 33,40,000 equity shares (2.93% of total share capital) on 21st Sep'26. The pledge with Catalyst Trusteeship Limited, held for the benefit of Aditya Birla Capital Limited against INR 160 Crore NCDs, was partially released following debt redemption. Consequently, Desai's encumbered holding decreased from 71,75,780 shares (6.30%) to 38,35,780 shares (3.37%), out of his total holding of 1,10,76,940 shares (9.73%).
Submission of proceedings of the 23rd Annual General Meeting of members of the Company held on September 30, 2026.
Annual General Meeting · 30 Sept 2026, 11:19 pm
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd
Acquisition/ Disposal of Shares · 30 Sept 2026, 5:42 pm
Catalyst Trusteeship Acquires 9.10% Pledge in Anupam Rasayan India Catalyst Trusteeship Limited, acting as Debenture Trustee on behalf of debenture holders, acquired encumbrance via pledge over 1,03,61,785 equity shares of Anupam Rasayan India Limited, representing 9.10% of total voting capital. The encumbrance was created in two tranches: 53,61,785 shares on 23rd Sep'26 and 50,00,000 shares on 25th Sep'26. Prior to this, Catalyst Trusteeship held no shares or encumbrances in the target company. Total equity share capital stands unchanged at INR 1.14B comprising 11,38,49,841 equity shares of Rs 10 each.
Submission of Press Release titled Anupam Rasayan concludes acquisition of Bliss GVS Pharma, makes third strategic step towards building an Integrated Global Pharma Platform.
Press Release · 29 Sept 2026, 1:23 am
Anupam Rasayan Concludes Acquisition of 48.2% Controlling Stake in Bliss GVS Pharma Anupam Rasayan completed the acquisition of a 48.2% controlling stake in Bliss GVS Pharma at ₹299 per share (~24x LTM earnings) via subsidiary Mates Visa Consultancy on 28th Sep'26. The deal was funded via a ₹300 crore term loan and ~₹1,450 crore raised through non-controlling instruments from investors led by Bain Capital. This expands Anupam Rasayan into finished dosage formulations. Post-consolidation of Anupam Rasayan, Tanfac, Jayhawk, and Bliss GVS, the combined platform expects pro-forma revenue of >₹4,000 crore and EBITDA of ~₹834 crore.
Allotment of Non Convertible Debentures.
Others (Uncategorized) · 22 Sept 2026, 5:09 am
Anupam Rasayan Allots INR 145 Cr NCDs to Aditya Birla Capital Anupam Rasayan India Ltd allotted 14,500 senior, secured, rated, unlisted, redeemable non-convertible debentures of face value INR 1,00,000 each, aggregating INR 145 Cr, to Aditya Birla Capital Ltd on a private placement basis on 21st Sep'26. The NCDs carry a 10.25% p.a. coupon with a 13-month tenure maturing on 21st Oct'27. Redemption includes INR 99,500 per debenture on or before 21st Oct'26 and INR 500 per debenture on 21st Oct'27. Proceeds will fund debt repayment, group company investments, and general corporate purposes.
Anupam Rasayan India Limited has informed the Exchange regarding Outcome of Board Meeting held on September 19, 2026.
Outcome · 20 Sept 2026, 3:25 am
The Board of Directors of the Company at its meeting held on September 19, 2026, has considered and approved the issuance of Non-Convertible Debentures on a private placement basis.
Others (Uncategorized) · 20 Sept 2026, 3:21 am
Anupam Rasayan Approves INR 160 Crore NCD Issuance to Aditya Birla Capital Anupam Rasayan India’s board approved issuing up to 16,000 secured, rated, unlisted, redeemable NCDs aggregating up to INR 160 crore at a 10.25% p.a. coupon on a private placement basis to Aditya Birla Capital. The 13-month tenure instrument has a deemed allotment date of 21st Sep'26 and final maturity on 21st Oct'27, with partial redemption of INR 99,500 per NCD by 21st Oct'26. Proceeds will fund debt repayment, group company investments, and general corporate purposes, secured primarily by pledged promoter shares and escrow hypothecation.
The Board of Directors of the Company at its meeting held on September 19, 2026, has considered and approved the issuance of Non-Convertible Debentures on a private placement basis.
Outcome · 20 Sept 2026, 3:16 am
Anupam Rasayan Approves INR 160 Crore NCD Issuance to Aditya Birla Capital Anupam Rasayan India’s board approved the private placement of up to 16,000 secured, rated, unlisted NCDs aggregating up to INR 160 crore to Aditya Birla Capital. The 13-month debentures carry a 10.25% p.a. coupon with a deemed allotment date of 21st Sep'26 and maturity on 21st Oct'27. Redemption includes INR 99,500 per NCD by 21st Oct'26, with the remaining INR 500 payable on maturity. Proceeds will fund debt repayment, group company investments, and general corporate purposes, secured via promoter share pledges and an escrow account charge.
Anupam Rasayan India Limited has informed the Exchange regarding Outcome of Board Meeting held on September 17, 2026.
Outcome · 18 Sept 2026, 2:26 am
Anupam Rasayan Approves Guarantee, Share Pledges, and Call Option for Subsidiary Financing Anupam Rasayan India approved key security documents to support financing for its wholly-owned subsidiary, Mates Visa Consultancy (MVCPL), and Purebliss Pharma Solutions on 17th Sep'26. MVCPL plans to issue up to INR 300 crore unrated unlisted senior secured NCDs. To secure this, Anupam Rasayan approved a 100% equity pledge in MVCPL, an unconditional corporate guarantee up to INR 300 crore, and granted Purebliss a call option to acquire MVCPL. Additionally, the company approved pledging its 15% equity stake in Purebliss for separate financing facilities.